Hypha Discovery Ltd to present Custom Fermentation Services at BIO 2010
5 May 2010, Maidenhead
Hypha Discovery Ltd, the UK custom fermentation and natural products discovery company announced that Dr Liam Evans, CEO, will present Hypha’s HD148 mTOR anticancer programme and natural products drug discovery technology platform at the at the Bio Industry Organisation (“BIO”) International Convention later today. BIO, being held this year in Chicago, USA, is the largest global event for the biotechnology industry. Dr Evans’ presentation will take place in the UK Innovation Zone, hosted by UK Trade & Investment (“UKTI”).
About Hypha Discovery Ltd
Hypha is a natural products company, focusing on the production of biologically useful compounds from Higher Fungi, using proprietary stimulatory custom fermentation methods. The company collaborates with drug discovery companies through the supply of the MycoDiverse™ library, a collection of 10,000 extracts and fractions with unusually high chemical novelty. Hypha has a pipeline of oncology and anti-infective pre-clinical projects from the MycoDiverse™ library, led by the HD148 series of mTOR kinase inhibitors, a synthetic series inspired by the discovery of a unique family of anticancer compounds from a tropical mushroom. Based in London and Maidenhead, the company also provides custom fermentation and compound purification contract services to other biotechnology companies.